PO.PR01.01 · 预防研究

在阿片类药物治疗项目(OTP)中向筛查不足人群提供HPV自采样检测以引入宫颈癌筛查后的结局

Outcomes after introduction of cervical cancer screening in an opioid treatment program (OTP) by offering HPV self-collect testing to an under-screened population

海报缩略图:在阿片类药物治疗项目(OTP)中向筛查不足人群提供HPV自采样检测以引入宫颈癌筛查后的结局
编号 2371 展板 7 时间 4/20 09:00–12:00 区域 Section 37 主讲 Elizabeth Swisher, MD
分会场 Cancer Disparities
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Elizabeth M. Swisher1, Mallory Davis2, Mayumi Rubin-Saika1, Enna Manhardt1, Emiko Oshima1, Renata Urban1, Stephem L. Cherne1, Eric Huang1, Tom Hutch2

1University of Washington, Seattle, WA,2We Care Daily Clinic, Auburn, WA

摘要 Abstract

中文摘要
患有阿片类药物使用障碍(OUD)的个体癌症筛查率较低。宫颈癌可通过筛查和治疗人乳头瘤病毒(HPV)相关癌前病变来预防。HPV自采样检测为将筛查扩展至先前未触及人群提供了机会,具有隐私、自主性的优势,并消除了对妇科服务临床要求的需要。我们评估了一种新颖的低门槛模式,将HPV自采样筛查整合到华盛顿州某大都市地区的一个实体OTP及其四个相关的移动药物单元中。在符合条件的患者(年龄25岁及以上、有宫颈、筛查逾期或不确定者)年度医疗更新就诊时提供自采样试剂盒,并在诊所卫生间私密采集。HPV拭子由华盛顿大学HPV分子病理实验室或Labcorp分析,涵盖全部14种已知高危型HPV(hrHPV)。结果阳性的受检者接受教育并获得符合指南的诊疗建议。诊所工作人员协助转诊至提供妇科服务的当地医疗机构,并追踪随访。研究的主要结局为筛查接受率、HPV阳性率和成功衔接后续诊疗的比率。从2024年6月24日至2025年10月31日,共评估了186名患者,包括29名(15.6%)美洲印第安人/阿拉斯加原住民、2名(1.1%)亚裔、20名(10.8%)黑人、2名(1.1%)夏威夷原住民/太平洋岛民、125名白人(67.2%)和9名(4.8%)西班牙裔。大多数为当前(72.9%)或既往(17.6%)烟草使用者。在168名(90.1%)符合筛查条件者(中位年龄40岁,范围22—65岁)中,150名(占符合条件者的89.3%)完成了筛查。没有失败或结果不确定的检测。在150份有结果的检测中,120份(80%)为HPV阴性,7份(4.7%)为HPV16/18阳性,23份(15.3%)为“其他”(非16/18)hrHPV阳性。患者在跟进hrHPV阳性检测时遇到各种结构性和社会障碍。在30份hrHPV阳性检测中,无一例失访,12名(40%)患者已完成随访,这通常需要医疗服务提供者多次协调尝试。其余患者处于转诊和预约的不同阶段。使用HPV自采样在OTP中提供宫颈癌筛查是可行的,并带来了较高的患者接受率。该人群既筛查不足又属高危,其hrHPV阳性率约为大多数美国筛查研究的两倍。我们以患者为中心的模式促进健康公平,并为减轻筛查不足社区的宫颈癌负担提供了可扩展的解决方案。
查看英文原文 English abstract
Individuals with opioid use disorder (OUD) have lower cancer screening rates. Cervical cancers are preventable through screening and treatment of human papillomavirus (HPV)-related pre-cancers. HPV self-collect tests provide opportunities to expand screening access to previously unreached populations, offering advantages of privacy, autonomy, and negating a clinic requirement for gynecological services. We evaluated a novel, low-barrier model for integrating HPV self-collect screening into a brick-and-mortar OTP and its four associated mobile medication units in a major metropolitan area in Washington state. Screening was offered with self-collection kits during annual medical update visits to eligible patients (those age 25 or above with a cervix who were overdue for screening or unsure) and collected privately in the clinic restroom. HPV swabs were analyzed at the University of Washington HPV Molecular Pathology Laboratory or Labcorp and included all 14 known high-risk HPV (hrHPV) types. Screened subjects with positive results received education and recommendations for guideline concordant care. Clinic staff facilitated referrals to local providers with gynecologic services and follow-up was tracked. The study's primary outcomes were the rates of screening uptake, HPV positivity, and successful linkage to follow-up care. From June 24, 2024 through October 31st, 2025, 186 patients were evaluated including 29 (15.6%) American Indian/Alaskan Native, 2 (1.1%) Asian, 20 (10.8%) Black, 2 (1.1%) Native Hawaiian/Pacific Islander, 125 White (67.2%) and 9 (4.8%) Hispanic. The majority were current (72.9%) or former (17.6%) tobacco users. Of 168 (90.1%) eligible for screening (median age 40 years, range 22-65 years), 150 (89.3% of those eligible) completed screening. There were no failed or inconclusive test results. Of 150 resulted tests, 120 (80%) were HPV-negative, 7 (4.7%) were HPV16/18+, and 23 (15.3%) were “other” (non-16/18) hrHPV+. Patients encountered a variety of structural and social barriers in following up hrHPV+ tests. Of the 30 hrHPV+ tests, no one has been lost to follow-up and 12 (40%) patients have completed follow-up, which often required multiple coordination attempts by providers. The remainder are in various stages of referral and scheduling. Providing cervical cancer screening was feasible in an OTP using HPV self-collection and resulted in high patient uptake. This population was both under-screened and high-risk with approximately double the hrHPV positivity rate found in most U.S. screening studies. Our patient-centered model promotes health equity and provides a scalable solution to reduce the burden of cervical cancer in under-screened communities.
利益披露 Disclosure
E. M. Swisher, Ideaya Biosciences Independent Contractor, Stock, Stock Option. M. Davis, None.. M. Rubin-Saika, None.. E. Manhardt, None.. E. Oshima, None.. R. Urban, None.. S. L. Cherne, None.. E. Huang, None.. T. Hutch, None.

← 返回 AACR 2026 检索